Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

The EMA, as well as the FDA in the US, have approved labelling for Wegovy that mentions that semaglutide has been ... people with a family history of thyroid cancer. In a statement, the EMA ...

Ozempic (semaglutide) is a subcutaneous injection ... Note that Ozempic has a boxed warning about the risk of thyroid cancer. A boxed warning is the most serious warning from the Food and Drug ...

In 2023, research on mice and rats suggested semaglutide — the powerful ingredient behind Wegovy and Ozempic — could raise the risk of one type of thyroid cancer: medullary thyroid cancer (MTC).

semaglutide (the active ingredient in Rybelsus) caused thyroid tumors in mice and rats. Animal studies don’t always predict what will happen in people. And no cases of thyroid cancer have been ...

Still, definitely tell your healthcare provider if you have a personal or family history of thyroid cancer before starting semaglutide treatment. It’s possible to experience significant ...

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...

HealthDay News — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based therapies and lead to significant weight loss in adults, according to ...

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for treating alcohol use disorder.